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Brief Communication
An Unusual Triad in Pediatric Neurology:
A Case Report on Cerebral Palsy, Epilepsy,
and Duchenne Muscular Dystrophy
Ruben G. F. Hendriksen, BSc1, Marlien W. Aalbers, MD, PhD1,2,
Jos G. M. Hendriksen, PhD1,3, Christine E. M. de Die-Smulders, MD, PhD4,5,
Govert Hoogland, PhD6,7, and Johan S. H. Vles, MD, PhD1,3
Abstract
We present a case of an unusual triad in pediatric neurology: a currently 12-year-old boy with cerebral palsy and epilepsy who was
later also diagnosed with Duchenne muscular dystrophy. We describe the clinical path that resulted in this exceptional diagnosis.
This case report illustrates how different neurological disorders may overshadow each other. In addition, it demonstrates that
every child with cerebral palsy and either an atypical clinical course or with inexplicable laboratory values—as well as every infant
boy born to a theoretical Duchenne muscular dystrophy carrier—should be subjected to additional investigations.
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Introduction
Cerebral palsy (CP) is a nonprogressive disorder of movement
and posture. It is attributed to a disturbed development of the
fetal or infant brain, which can thus occur in the prenatal, peri-
natal, or postnatal period. Since cerebral palsy affects 1 in 400
children, it is the most common developmental disorder asso-
ciated with lifelong disability.1 Although the true pathophysiol-
ogy of cerebral palsy has not yet been fully elucidated, it
appears to depend on a complex interplay between genetic pre-
disposition and multiple environmental triggers such as extreme
prematurity, traumatic brain injury, or intrauterine infection.
The clinical presentation of cerebral palsy can vary enormously
and partly depends on the affected areas in the central nervous
system. Children with cerebral palsy initially present with
delayed achievement of motor milestones, abnormal muscle
tone, disturbances in posture, and muscle weakness. Children
with cerebral palsy also more often encounter problems with
learning. Furthermore, seizures are common in these children,
and up to one-third is diagnosed with epilepsy.2
A complete history and physical examination are of essen-
tial importance in diagnosing cerebral palsy. In addition, the
diagnosis can be facilitated by imaging techniques such as
brain ultrasound, magnetic resonance imaging (MRI), and
computed tomography (CT) that demonstrate central nervous
system damage in 80% of children with cerebral palsy.3
Neuromuscular disorders constitute another frequent cause
of aberrant development. Duchenne muscular dystrophy is the
most common neuromuscular disorder and affects
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approximately 1 in 3500 to 5000 live male births. Patients with
Duchenne muscular dystrophy carry a mutation in the DMD
gene, located on the short arm of the X-chromosome in band 21
(Xp21), which arises either as a de-novo mutation or via inheri-
tance. It is characterized by a progressive loss of muscle func-
tion and mass. The first presenting symptoms, which manifest
around the age of 4, consist of pseudo-hypertrophy of the calf
muscles, delayed motor abilities and milestones, frequent falls,
and a typical way of getting in upright position, known as
Gower’s maneuver. Without adequate symptomatic manage-
ment, boys with Duchenne muscular dystrophy become wheel-
chair dependent before their teens. At some point during the
progression of the disease, cardiac and respiratory complica-
tions emerge; without interventions, the mean age at death is
around 19 years. Clinical management of these complications
is therefore of vital importance, since such management is able
to extend both the ambulatory period and the average life
expectancy.4
Over the last decades, it has become increasingly clear that
Duchenne muscular dystrophy is more than a muscle disease,
as there is also specific involvement of the brain, resulting in
lower general intellectual capacities5, and learning and neurop-
sychiatric disorders.6,7 Moreover, it has been shown that
epilepsy is more common in Duchenne muscular dystrophy
populations.8,9 These latter comorbidities constitute a group
of additional brain-related disorders that also have been
reported in cerebral palsy as mentioned earlier.
A boy, in whom the diagnosis of Duchenne muscular dys-
trophy is suspected, can subsequently be diagnosed by genetic
testing, sometimes in combination with a muscle biopsy if a
mutation cannot be identified.4 Diagnosis is approximately
made at the age of 5 years. Furthermore, prenatal diagnosis
of Duchenne muscular dystrophy is possible if the mother is
suspected to be a carrier.
In line with a case report by Rha and colleagues10 who
reported on a belated diagnosis of cerebral palsy in a patient
with Becker muscular dystrophy, a milder form of Duchenne
muscular dystrophy, we here report the case of a boy who
was diagnosed with Duchenne muscular dystrophy during his
follow-up for both cerebral palsy and epilepsy. The aim of
the case report is to describe and demonstrate the possible
concomitant appearance of Duchenne muscular dystrophy,
cerebral palsy, and epilepsy, which has serious implications
for diagnosis, therapy, and prognosis of the patient. Further-
more, we aim to show that pediatricians and pediatric neu-
rologists, in particular, should remain alert if the course of
cerebral palsy is evolving differently from what is usually
expected (as based on medical history and MRI results) and
should perform additional investigations such as a creatine
kinase screening.
Case Report
A currently 12-year-old boy was born to a Dutch couple. There
was a possible positive family history for Duchenne muscular
dystrophy, as the mother of the patient had 2 uncles who
presumably had a muscle disorder, most likely Duchenne mus-
cular dystrophy. However, a diagnosis was never made, and the
men died at the age of 17 and 27. Because of the family history,
the mother had undergone genetic screening for Duchenne
muscular dystrophy in 1992 by means of creatine kinase
screening, DNA screening of both X-chromosomes, and a mus-
cle biopsy. The DNA screening was performed by means of
genomic DNA (gDNA) hybridization with dystrophin probes,
which did not detect any deletions in the dystrophin genes.
Since all 3 investigations yielded normal results, the mother
of our patient was explained that she was probably not a carrier
of Duchenne muscular dystrophy (the estimated risk of being a
carrier was therefore 10%). However, it was mentioned that
this possibility was not completely ruled out, since dystrophin
expression and creatine kinase serum levels can be normal in
carriers. Furthermore, the sequence of the possible DMD gene
mutation in the family was unknown, thus impeding a fully
accurate—that is, with 100% certainty—detection of possible
DMD gene mutations in the maternal X-chromosomes.
The boy was delivered by a Cesarean section at the prema-
ture age of 32 weeks and 2 days because of fetal distress based
on a maternal infection and asphyxia. His body weight was
1955 g. Despite that mentioned earlier, he initially obtained a
high Apgar score of 8 over 9.
At day 8, he was admitted to a neonatal intensive care unit
with a neonatal necrotic enterocolitis. He remained here for
4 weeks, after which he was discharged with a weight of
2400 g and a frontal occipital circumference of 33.1 cm.
An initial ultrasound of the brain did not reveal any abnorm-
alities. However, after 1 month, another ultrasound demon-
strated cyst formation, particularly frontal and parietal
(periventricular leukomalacia degree 3), with enlarged peri-
ventricular liquor space. Subsequently, an electoencephalo-
graphy (EEG) was made, which showed a normal
background pattern according to his age without epileptiform
activity yet with moderate focal abnormalities. An MRI made
at the age of amenorrhea duration þ 40 weeks (ADþ40)
showed a PVL degree 4 with cyst formation, mainly tempo-
rally located and left more than right (Figure 1). The parents
were informed about the prognosis, which likely included
that their son would become spastic in his lower limbs. Addi-
tionally, it was mentioned that epilepsy and cognitive prob-
lems could possibly develop at a later age.
At the age of 3 months abnormal repeated general move-
ments were present. After 6 months, cerebral palsy was diag-
nosed as he clinically presented with axial hypotonia while
having hypertonia in his extremities. Moreover, he presented
with hyperreflexia and general movement abnormalities at dif-
ferent moments during follow-up.
From the age of approximately 7 months, he developed
Salaam spasms, and in a later stage absence seizures with head
nodding followed by tonic rigidity as based on multifocal epi-
lepsy. This was subsequently confirmed by EEG registration,
which revealed the epilepsy was originating from left and right
occipital areas. The clinical picture further deteriorated, and he
lost his visual ability. He was then diagnosed with a
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symptomatic West syndrome, since the EEG did not show any
signs of hypsarrhythmia.
In line with the clinical picture of PVL, the boy was, at the
age of 3½, not able to stand and walk independently. At the age
of 3 years and 10 months, he was evaluated by a pediatrician
for constipation, probably as a side effect of the use of the
antiepileptic drugs. An extensive hematological and biochem-
ical workout revealed increased liver enzymes: aspartate trans-
aminase, 299 IU/L; alanine transaminase, 206 IU/L; lactate
dehydrogenase, 1644 IU/L; and creatine kinase, 13 485 IU/L
(normal <200 IU/L). Initially, liver disease was considered and
tested for (i.e. hepatitis A, B, and C-; Epstein Barr virus; and
cytomegalovirus serology, which turned out to be all negative)
and also the family history of the mother was taken into
account. On physical examination, a boy with severe growth
and mental retardation was seen. The frontal–occipital circum-
ference was 48.0 cm. Furthermore, he was hypotonic, which
was in sharp contrast to the past when he was initially hyper-
tonic. Moreover, his reflexes were diminished or even absent,
while they used to be vivid at the early stages of his life.
Additionally, no (pseudo)hypertrophic calves were observed
nor were contractures present.
Working out the differential diagnosis, some of the afore-
mentioned signs, such as the family history and the increased
creatine kinase levels, pointed in the direction of a neuromus-
cular disorder, whereas other features did not. This prompted,
however, additional investigations at the age of 4; a muscle
biopsy and genetic testing were initiated. The muscle tissue
appeared to be devoid of dystrophin. The genetic testing also
confirmed the suspected Duchenne muscular dystrophy, as
exon 61 of the Duchenne muscular dystrophy gene was dupli-
cated. The mother, who never had any complaints, subse-
quently decided not to get tested for this mutation, as it
would not have consequences for her or her offspring. That
is, her son born with Duchenne muscular dystrophy was her
second child (the oldest son did not have Duchenne muscular
dystrophy), and she and her husband did not have a desire for
more children. Therefore, it cannot be ascertained whether the
dystrophin mutation of our patient was inherited from the
mother or whether it was a de-novo mutation. After the diag-
nosis of Duchenne muscular dystrophy was made, our patient
was eventually able to stand up individually and walk a short
distance at the age of 5½ years. It was noticed that for standing
up, he pulled himself in upward direction, thereby resembling
Gower’s maneuver. At the age of 7, he lost the ability to walk
again.
After having established the diagnosis for Duchenne mus-
cular dystrophy, he was psychologically tested at the age of
8 years, which revealed a developmental age of 9 months (Kent
Infant Development Scale), showing serious retardation. He
started rehabilitation therapy, physiotherapy, and physical ther-
apy. The parents eventually decided not to start prednisone
treatment. The patient currently visits a day care center for
mentally retarded children.
Discussion
We describe a patient with an atypical course of cerebral palsy,
epilepsy, and also Duchenne muscular dystrophy. Although a
concomitant diagnosis of cerebral palsy in Becker muscular
dystrophy has already been documented, this report describes
the first case with this unusual triad of neuropediatric disorders.
Although these disorders most likely have a different etiology,
the simultaneous presentation is highly uncommon and there-
fore particularly interesting. Most probably, the cerebral palsy
and malignant epilepsy syndrome are the consequence of the
pre- and perinatal asphyxia, especially since 50% of cases of
cerebral palsy result from hypoxic events with irreversible cell
death.11 Also, in cerebral palsy, the prevalence of epilepsy is
much higher than in the normal population, certainly when
there are structural abnormalities visible on MRI. The dystro-
phin deficiency, which was later diagnosed at the age of four
years, is the result of a duplication of exon 61 of the DMD
gene, consequently disrupting the reading frame since this
causes a frame-shift mutation.
In this particular case, the patient was initially diagnosed
with cerebral palsy because he showed hypertonia, abnormal
movement, and hyperreflexes. The clinical picture then slightly
changed over time to a state of areflexia and hypotonia. Based
on the delayed walking and motor milestones and especially
the positive family history, one might have suspected the pres-
ence of a neuromuscular disorder. However, cerebral palsy is
also characterized by delayed walking and delayed motor mile-
stones, and these characteristics were therefore interpreted as a
consequence of the motor and ambulatory problems associated
with cerebral palsy. Moreover, on neurological examination,
there were no other evident signs of Duchenne muscular dys-
trophy such as pseudo-hypertrophy. Since our patient was not
able to stand up independently before the diagnosis of Duch-
enne muscular dystrophy was made, a Gower’s maneuver
could not be observed either. This has also impeded a straight-
forward diagnosis of Duchenne muscular dystrophy, as this
maneuver provides clinicians often with an easy but valuable
Figure 1. Transversal T2-weight magnetic resonance imaging
sections revealing periventricular leukomalacia, mainly anteriorly,
and posteriorly seen of both lateral ventricles, suggesting perinatal
asphyxia.
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tool that triggers further diagnostic investigation.4 Thus, the
spasticity overshadowed the Duchenne symptoms to a certain
extent here. The atypical course of the clinical picture and the
elevated creatine kinase levels prompted further analysis. This
enabled the diagnosis of Duchenne muscular dystrophy at the
age of 4 years and 1 month, which is nevertheless still below
the average age of 4.9 years.12
One year and 4 months after the diagnosis Duchenne mus-
cular dystrophy was made, our patient started to walk. Regard-
ing walking in cerebral palsy, it is known that most children
lose the ability to walk around puberty, mainly because of a so-
called crouched gait as a consequence of a combination of
factors including growth, weight gain, contractures, and par-
esis. In our case, the boy lost the ability to walk already at the
age of 7 years, which was not due to crouched gait but rather
weakness, the most important clinical characteristic of Duch-
enne muscular dystrophy.
The presence of Duchenne muscular dystrophy might have
influenced the development of seizures: A lack of dystrophin
can theoretically result in a larger susceptibility for the devel-
opment of seizures (see Hendriksen et al8). The latter is clini-
cally reflected by an increased prevalence of epilepsy in
Duchenne muscular dystrophy.9 The mutation of our patient
in exon 61 would affect all 3 dystrophin protein (Dp) isoforms
expressed in the brain (i.e. Dp427, Dp140, Dp71). As particu-
larly the absence of Dp427 and Dp71 might lead to increased
neuronal excitability (both by their own distinctive mechan-
isms), this specific mutation may result in an accumulated risk
of hyperexitation.8 Nonetheless, it is unclear to what extent the
lack of brain dystrophin has contributed to the epileptogenesis
of this patient. Although it seems far more likely that the epi-
lepsy resulted from perinatal asphyxia, a combinational inter-
play between a predisposing dystrophin absence and a
precipitating perinatal hypoxia could constitute a theoretical
third explanation here.
In addition to epilepsy, cognitive problems are more often
seen in Duchenne muscular dystrophy as well and can, again,
partly be clarified by a lack of several brain dystrophin iso-
forms, particularly Dp71. Furthermore, it has been proposed
several times that distal mutations, such as in this case, could
result in more profound cognitive deficits.7 Therefore, it would
have been interesting to discern the cognitive level of the two
maternal uncles in order to relate this to their DMD gene muta-
tions. Since both are unknown, the latter is unfortunately not
possible. However, it is, as stated above, more plausible that the
cognitive deficits result from the oxygen deprivation, as this is
more often encountered in cerebral palsy.
This is the second case report on a patient who was diag-
nosed with cerebral palsy and a neuromuscular disorder yet the
first who was diagnosed with cerebral palsy and Duchenne
muscular dystrophy. Making a clinical diagnosis of cerebral
palsy and a concomitant neuromuscular disorder can be chal-
lenging, as signs from both disorders can overshadow each
other.10 Diagnostic overshadowing is an important phenomenon
in clinical practice that should not be underestimated. This term
was introduced in 1982 and has recently been described in a
population study of children with diverse neurological disor-
ders with respect to attention-deficit hyperactivity disorder as
comorbidity.13
In conclusion, epilepsy, cerebral palsy, and Duchenne mus-
cular dystrophy can be comorbidities, although they are not
necessarily based on the same underlying pathology. Because
Duchenne muscular dystrophy and cerebral palsy share clinical
features, the diagnosis of each can be hampered. In line with
the proposal of Ciafaloni and colleagues,12 this case report
illustrates the importance of creatine kinase screening in boys
with unexplained developmental delay, as the increased crea-
tine kinase levels, as part of general blood, prompted further
analysis. Furthermore, as this case report also demonstrates,
such creatine kinase screening (preferably in the first weeks
of life) is highly indicated in infant boys who are born to a
theoretical carrier of Duchenne muscular dystrophy, even if the
probability of carriage is minor (ie, less than ten percent). Next
to that, it underlines the importance of a multidisciplinary
approach, as this approach allowed a timely diagnosis, despite
the fact that Duchenne muscular dystrophy was initially barely
visible. It is of vital importance to diagnose a concomitant
disorder such as Duchenne muscular dystrophy next to cerebral
palsy, since this affects not only therapeutic aspects such as
timely initiation of (corticosteroid) therapy but also timely
beginning of genetic counseling. Additionally, the prognosis
of the diseases is different, and the health-related quality of life
appears to be differently affected in both children with cerebral
palsy and boys with Duchenne muscular dystrophy.14,15 There-
fore, clinicians working in the (neuro)pediatric fields should be
aware of this uncommon triad. Although this triad rarely
occurs, it shows that every child with cerebral palsy, either
with an atypical course or with inexplicable laboratory values,
should be subjected to additional investigations for possible
comorbidities that might be overshadowed.
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